No Data
addex therapeutics (ADXN.US) will release its financial report before the market opens on November 11th.
$Addex Therapeutics(ADXN.US)$ will release its financial report before the market opens on November 11th, investors please take note. How was its performance before? $Addex Therapeutics(ADXN.US)$ had a revenue of 0.115277 million francs, a net income of 12.878632 million francs, and an EPS of 9.6 francs in 2024/Q2. In 2023/Q3, the revenue was 0.327733 million francs, the net income was -2.61707 million francs, and the EPS was -3.6 francs. Futubull reminder: 1. Hong Kong and U.S. stocks are up.
Why IRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
What Makes Addex Therapeutics (ADXN) a New Buy Stock
H.C. Wainwright Maintains Addex Therapeutics(ADXN.US) With Buy Rating, Maintains Target Price $30
Buy Rating Affirmed for Addex Therapeutics Amid Promising Clinical Developments and Strategic Neurosterix Spinout
Earnings Call: Addex Therapeutics Reports Half-year Financials and R&D Updates
No Data
No Data